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Background: Common variants of the PPARA gene have been found to associate with ischaemic
heart disease in non diabetic men. The L162V variant was found to be protective while the C2528G
variant increased risk. L162V has also been associated with altered lipid measures. We therefore
sought to determine the effect of PPARA gene variation on susceptibility to myocardial infarction in
patients with type 2 diabetes. 1810 subjects with type 2 diabetes from the prospective Go-DARTS
study were genotyped for the L162V and C2528G variants in the PPARA gene and the association
of the variants with incident non-fatal myocardial infarction was examined. Cox's proportional
hazards was used to interrogate time to event from recruitment, and linear regression for analysing
association of genotype with quantitative clinical traits.
Results: The V162 allele was associated with decreased risk of non-fatal myocardial infarction (HR
= 0.31, 95%CI 0.10–0.93 p = 0.037) whereas the C2528 allele was associated with increased risk
(HR = 2.77 95%CI 1.34–5.75 p = 0.006). Similarly V162 was associated with a later mean age of
diagnosis with type 2 diabetes and C2582 an earlier age of diagnosis. C2528 was also associated
with increased total cholesterol and LDL cholesterol, which did not account for the observed
increased risk. Haplotype analysis demonstrated that when both rare variants occurred on the
same haplotype the effect of each was abrogated.
Conclusion: Genetic variation at the PPARA locus is important in determining cardiovascular risk
in both male and female patients with diabetes. This genotype associated risk appears to be
independent of the effect of these genotypes on lipid profiles and age of diagnosis with diabetes.
Background
Dysregulation of fatty acid metabolism plays a pivotal
role in the aetiology of type 2 diabetes [1], and explains,
at least in part, the association between obesity, type 2
diabetes and cardiovascular disease (CVD). PPARα is a
member of the nuclear receptor super-family of ligand-
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polyunsaturated fatty acids and the fibrate class of lipid-
lowering drugs [2]. It is expressed at high levels in several
cell types involved in the atherosclerotic process [3], and
its activation has beneficial effects on plasma lipids,
endothelial function and markers of inflammation [4].
Thus, the PPARA gene is a strong candidate for a genetic
determinant of CVD risk in people with type 2 diabetes
[5].
The PPARA gene has been screened for common variation
[6-8]. The most studied variant is the leucine 162 valine
(L162V) polymorphism, present at allele frequencies
between 5 and 10%, and situated in the DNA binding
domain. Functional studies have demonstrated that the
V162 allele is more active in vitro [7,9], and the V162 allele
has been associated with altered plasma lipid levels
[6,8,10], delayed progression of angiographically deter-
mined CV disease in the Lopid Coronary Angiography
Trial (LOCAT), and reduced risk of ischemic heart disease
in the Second Northwick Park Heart Study (NPHS2) [11].
A second, more common, G→C variant situated in intron
7 (G2528C) is in partial allelic association with the L162V
variant and shows opposing effects on cardiovascular risk
and cardiac growth [9,11]. Recently it has been demon-
strated that haplotypes of these variants in association
with a further A→C variant in intron 1 influence age of
onset of type 2 and time to requiring insulin [12].
PPARα activators improve the dyslipidemia associated
with type 2 diabetes and may be particularly beneficial in
lowering risk of CVD in subjects with type 2 diabetes or
metabolic syndrome [13]. We therefore investigated the
association between PPARA gene variation with risk of
CVD and diabetes related traits in Caucasian subjects with
type 2 diabetes participating in the prospective popula-
tion-based Genetics of Diabetes Audit and Research in
Tayside Scotland (Go-DARTS) study [14-16].
Results
The clinical characteristics of the genotyped cohort are
shown in table 1. The allele frequencies of both polymor-
phisms were consistent with those previously published
for European non-diabetic populations (table 2). The two
polymorphisms were both in Hardy-Weinberg equilib-
rium and were in significant linkage disequilibrium D' =
0.204 p =< 0.00001. Estimated haplotype frequencies
indicated very similar values with those previously pub-
lished (table 3). There was little evidence that the geno-
types either singly, or when included in the model
together, were associated with blood pressure or lipid
measurements (table 4). V162 was associated with a gen-
erally more cardioprotective profile with V/V homozy-
gotes having lower systolic and diastolic blood pressure,
lower LDL cholesterol and higher HDL cholesterol than L/
L homozygotes, although none of these differences were
significant. Conversely C2528 homozygotes had a small
but significantly higher total cholesterol and calculated
LDL cholesterol compared to G/G homozygotes. We also
Table 1: Clinical characteristics of the Go-DARTS cohort
No of individuals 1810 (54% male)
Age at recruitment (years) 63.1 (9.6)
Age at diagnosis 54.9 (9.0)
Body Mass Index (kg/m2) 30.5 (5.4)
Insulin treatment 839 (44.1%)
Smoking History 958 (50.4%)
Prevalent cerebrovascular disease 67 (3.5%)
Prevalent angina 178 (9.4%)
Previous myocardial infarction 323 (17.0%)
Data shown are mean (SD) for continuous variables and n (%) for categorical variables.
Table 2: PPARA genotype distribution and allele frequencies in the Go-DARTS cohort. The corresponding allele frequencies from the 
Second Northwick Park Heart Study (NPHS2)11 is shown for comparison.
n n
L162V L/L 1573 G2528C GG 1216
L/V 224 GC 529
V/V 13 CC 64
1810 1809
Go-DARTS allele 
freq.
0.069 (0.061–0.077) 0.182 (0.169–0.194)
NPHS allele freq. 0.063 0.174Page 2 of 7
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type 2 diabetes, with the V162 allele being associated with
a significantly later age of diagnosis and the C2528 allele
with a significantly earlier age of diagnosis (Table 5).
When we considered haplotypes we found that V162-
G2528 was associated with almost a 4 year delay in diag-
nosis with diabetes compared to the common L162-
G2582 haplotype (p = 0.004). This association was com-
pletely abrogated when C2528 occurred together with
V162 as a haplotype.
During a median follow up time 49.6 months there were
108 non-fatal myocardial infarction events and 355
deaths from all causes. In a fully adjusted Cox's propor-
tional hazards model (table 6) we found that V162 was
significantly protective against non-fatal myocardial inf-
arction (HR 0.31, 95%CI 0.10–0.93, p = 0.037), while the
C2528 variant was associated with a significantly higher
risk of non-fatal myocardial infarction (HR 2.77, 95%CI
1.34–5.75, p = 0.006). This association was found to be
similar in both sexes. Neither variant demonstrated any
evidence of an association with risk of myocardial infarc-
tion when considered in isolation. Again, when we con-
sidered haplotypes, we found that compared to the
haplotype with both common alleles, the haplotype
L162-C2528 was associated with a significantly increased
cardiovascular risk (HR 1.68 95%CI 1.16–2.43 p = 0.006)
and the V162-G2528 a decreased risk although in this case
this was not significant (HR 0.54, 95%CI 0.20–1.48, p =
0.23). Again the relative associations of each variant were
completely abrogated when they occurred together on the
same haplotype. The inclusion of total cholesterol in the
model did not attenuate these observed associations but
rather further strengthened them (V162: HR 0.28, 95% CI
0.09–0.89, p = 0.031 and C2528: HR 2.87, 95%CI 1.38–
5.95, p = 0.005) demonstrating that the increased risk
Table 3: Estimated Haplotype frequencies in Go-DARTS. Frequencies in NPHS2 are given for comparison
Haplotype Go-DARTS NPHS2
L162-G2528 0.802 0.804
L162-C2528 0.130 0.132
V162-G2528 0.016 0.021
V162-C2528 0.052 0.041
Table 4: Biochemical parameters at genotyping. Mean and 95% confidence intervals of all readings taken within 2 years prior to 
enrolment in study
L162V
L/L L/V V/V
BMI 30.5 30.2–30.7 30.7 30.0–31.4 28.9 26.0–31.9
SBP mmHg 142.5 141.7-141.3 141.3 139.3–143.3 134.9 126.7–143.1
DBP mmHg 79.5 79.1–79.8 79.7 78.6–80.7 77.3 73.1–81.5
Cholrat† mmol/
L
4.5 4.4–4.6 4.8 4.5–5.0 4.3 3.3–5.3
Chol mmol/L 5.2 5.2–5.3 5.3 5.1–5.4 5.3 4.8–5.8
Trigs mmol/L 2.7 2.6–2.8 2.8 2.6–3.1 2.4 1.3–3.5
HDL mmol/L 1.22 1.20–1.24 1.23 1.20–1.28 1.31 1.13–1.50
LDL mmol/L 2.89 2.84–2.92 2.89 2.78–3.00 2.92 2.42–3.41
G2528C
G/G G/C C/C
BMI 30.5 30.2–30.8 30.4 29.9–30.8 31.40 30.1–32.7
SBP mmHg 142.5 141.7–143.4 142 140.7–143.3 140.2 135.5–143.9
DBP mmHg 79.5 79.0–79.9 79.7 79.0–80.3 78.2 76.3–80.1
Cholrat† mmol/
L
4.49 4.37–4.60 4.74 4.57–4.91 4.51 4.03–4.98
Chol mmol/L 5.20 5.15–5.25 5.26 5.18–5.34 5.56 5.33–5.79*
Trigs mmol/L 2.73 2.62–2.83 2.75 2.59–2.91 2.65 2.18–3.12
HDL mmol/L 1.22 1.20–1.24 1.23 1.20–1.25 1.25 1.17–1.34
LDL mmol/L 2.88 2.83–2.92 2.88 2.81–2.95 3.22 3.01–3.44*
*P < 0.05 ANOVA co-dominant model
† Cholrat = Total cholesterol/HDL RatioPage 3 of 7
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terol levels. When a combined endpoint of death from all
cause, and non-fatal myocardial infarction was consid-
ered in the same model it was found that the V162 contin-
ued to demonstrate a reduced risk of an event although
the association was attenuated (HR 0.52, 95%CI 0.28–
0.98, p = 0.044). C2528 again demonstrated an increased
risk although this was now weak and borderline non-sig-
nificant (HR 1.52, 95% CI 0.99–2.31, p = 0.052).
Discussion
It has been previously demonstrated that two common
variants at the PPARA locus are associated with opposing
risks of development of atherosclerotic vascular disease
and myocardial infarction in two separate populations of
non-diabetic male subjects taking part in the LOCAT and
NPHS2 studies [11]. Individuals with type 2 diabetes are
however particularly susceptible to atherosclerotic mac-
rovascular disease, and PPARα activators such as the
fibrate group of drugs appear to be particularly beneficial
in reducing cardiovascular events in this group of patients
[13]. In this study we have confirmed the observation that
V162 is associated with a decreased risk and the C2528
variant is associated with an increased risk of cardiovascu-
lar disease and that this observation can be extended to
individuals with type 2 diabetes. We also found that the
association is similar in both male and female individu-
als. Finally we confirm a recent finding that these variants
are associated with opposing influences on age of diagno-
sis with type 2 diabetes [12], and that the C2528 variant is
also associated with significantly higher total cholesterol
and calculated LDL cholesterol levels.
Table 5: Influence of genotype and inferred haplotypes on age diagnosed with type 2 diabetes.
Age diagnosed
Beta 95% CI p
V162* 2.6 0.2–5.1 0.034
C2528† -1.1 -2.0–0.2 0.022
Haplotype
L162-G2582 Ref
L162-C2528 -0.40 -1.25 – 0.45 0.36
V162-G2528 3.89 1.26 – 6.51 0.004
V162-C2528 -0.28 -1.65 – 1.10 0.69
*Co-dominant model
† Dominant model
Both variants included in the model
Table 6: Prospective model of PPARA variants and non-fatal myocardial infarction risk in the Go-DARTs cohort. A full set of data was 
available on 1806 individuals, 108 recorded non fatal myocardial infarctions during the period of observation, with a total of 94497.6 
months of observation. Both PPARA variants were analysed using a co-dominant model.
Hazard Ratio 95% CI P
V162 0.31 0.10 0.93 0.037
C2528 2.77 1.34 5.75 0.006
Smoking 1.39 0.93 2.10 0.112
Gender 0.72 0.48 1.08 0.107
Age at recruitment 1.05 1.02 1.07 <0.001
Insulin treatment 2.56 1.69 3.89 <0.001
Prevalent angina 5.64 3.80 8.40 <0.001
Prevalent cerebrovascular 
disease
1.29 0.67 2.51 0.445
Prevalent myocardial 
infarction
3.90 2.60 5.81 <0.001
Haplotypes
L162-G2582 Ref
L162-C2528 1.68 1.16–2.43 0.006
V162-G2528 0.54 0.20–1.48 0.23
V162-C2528 0.96 0.48–1.94 0.91Page 4 of 7
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importance of genetic variation at the PPARA locus
although most have concentrated on lipid levels and have
considered the L162V variant in isolation. These studies
have been inconsistent indicating that L162V may influ-
ence levels of cholesterol or other lipoproteins, depending
on the population analysed [6,8,10,12,17,18], while
other studies have found no evidence for such an associa-
tion [19,20]. These inconsistencies may be due in large
part to differing environments, genetic background and
diseased status (including medications prescribed)
between the populations considered. For instance the rel-
ative concentration in the diet of saturated to polyunsatu-
rated fat has recently been demonstrated to significantly
affect association of L162Vgenotype with lipoprotein pro-
file [21,22]. Furthermore, it is likely that there will be dif-
ferential usage of fibrate (as well as other lipid modifying)
drugs between individuals with type 2 diabetes and non-
diabetic populations which may also influence the lipid
levels differentially by PPARα haplotype [23,24]. Gene/
gene interactions may also be important as evidenced by
the observation that variants in the PPARD and APOE
genes can influence the observed association [10,20]. The
inevitability of gene/environment interactions, and the
observed inconsistency between studies, illustrate the dif-
ficulties of considering single measures of quantitative
traits. Such measures are likely to vary considerably over
an individual's lifetime, depending on health status and
diet. Importantly, the clinical measures in this study were
a mean of multiple measures taken over up to a three year
period and therefore represent a limited integration of
such temporal fluctuations.
In this study we found that the G2582C variant, but not
the L162V variant, influenced lipid levels and this associ-
ation was not influenced by L162V. The difference
between the mean values of LDL cholesterol for GG indi-
viduals compared to CC was rather small (0.36 mmol/L)
and even in this high risk population did not account for
the increased cardiovascular risk associated with C2582.
This was not unexpected, as in keeping with the previous
studies in non-diabetic men, inclusion of total cholesterol
or LDL cholesterol in the model did not affect the associ-
ation with cardiovascular outcomes, indicating that the
increased risk associated with the C2528 variant is not
likely to be through its influence on lipid levels.
Few studies have considered cardiovascular disease or
considered variants other than the L162V. One recent
study also demonstrated a non significant trend towards a
protective effect of V162 in individuals with diabetes [19].
This study did not consider the G2825C variant. The
present study however confirms that the V162 variant is
protective against nonfatal myocardial infarction, while
the C2528 variant is associated with an increased risk in
this population with type 2 diabetes. These observations
also appear to affect overall mortality in this population.
This apparent consistency across studies with respect to
cardiovascular events probably reflects the small, though
global, modulation in phenotype acting across an individ-
ual's lifetime due to the slight changes in activity of
PPARα associated with each variant. Unlike single meas-
ures of lipids or lipoproteins, this is less likely to be
effected by temporal environmental changes. This is also
likely to be true for clinical events such as age of diagnosis.
In the previous study that considered age of diagnosis a
further variant in intron 1 of PPARA was used to construct
haplotypes with L162V and G2825C [12].
In this study, as in ours, the C2825 was associated with an
earlier age of diagnosis, with the V162 allele being associ-
ated with protection from early diagnosis, in a manner
consistent with the modulation of CVD risk. This is the
first study to present the association with age-of-diagnosis
of type 2 diabetes in the same population with the associ-
ation with cardiovascular risk, and we can state that inclu-
sion of age of diagnosis does not modulate the observed
associations with cardiovascular risk and vice-versa, dem-
onstrating that these are independent observations. This is
not surprising, as PPARA variation is associated with CVD
risk regardless of diabetic status.
The G2825C variant is in a non-coding region (intron 7)
and therefore unlikely to be a directly causal variant, how-
ever several other studies have indicated its potential bio-
logical importance [9,11,12] and also a reduced response
to fibrate therapy [25]. These observations together with
that of PPARα activation through fibrate therapy have
given rise to the suggestion that the C2528 variant is asso-
ciated with reduced RNA transcription and hence lower
PPARα levels. Although this suggestion together with a
mechanism remains to be demonstrated, it is probably
due to a further (as yet) unidentified variant in or near the
PPARA gene.
We have previously demonstrated a similar situation in
the PPARG locus in which the biological effect of a variant
with probable functional consequences is consistently
modified in an opposing manner by the presence of a var-
iant for which a function is difficult to ascribe [14,15].
Given the role of the PPARs as master controllers of energy
metabolism it is likely, as the accumulating evidence
appears to suggest, that they will manifest epistasis and
balanced polymorphism allowing for rapid adaptive evo-
lutionary response to widely differing environmental
challenges. Indeed, the existence of widespread, balanced
variation has recently been suggested for genes involved
in complex traits [26].Page 5 of 7
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We have confirmed the potential importance of genetic
variation at the PPARA locus in modulating susceptibility
to cardiovascular disease, and have shown that this asso-
ciation is relevant to individuals with type 2 diabetes.
Methods
In the Tayside region of Scotland detailed clinical infor-
mation on all individuals with diabetes mellitus is
recorded on a continuously updated electronic clinical
information system known as DARTS (Diabetes Audit and
Research in Tayside Scotland) [16]. Validated, region-
wide electronic record-linkage techniques facilitate the
identification of individuals with diabetes in the Tayside
population with a sensitivity of 97% [16]. Relevant clini-
cal data is linked to databases containing all inpatient
hospital admissions in Tayside from 1980 with diagnostic
codes from ICD-9/10 (International Classification of Dis-
eases, ninth and tenth revisions), and records of death cer-
tificates from the registrar general. This automated
electronic follow-up is manually validated through a con-
tinuous cycle of review by dedicated study clinicians. Inci-
dent cardiovascular events in this population have been
described previously [27].
Following written informed consent from individuals reg-
istered on DARTS, blood samples for genetic studies have
been collected, thereby creating a genetic sub-study
known as Go-DARTS. Rigorous compliance with NHS
data protection and encryption standards is maintained
and the study was approved by the local research ethics
committee.
The PPARα L162V and G2528C genotypes were deter-
mined in 1,810 individuals all of whom were Caucasian
with type 2 diabetes diagnosed between the age of 35 and
70 years. Taqman (Applied Biosystems) allelic discrimina-
tion assays were used. The primers and probes used for the
allelic discrimination assays were as follows: L162V For-
ward primer-CAGAAACAAATGCCAGTATTGTCG, Reverse
primer-GGCCACCTTACCTACCGTTGTG, L162 probe
(FAM labelled) – TTCACAAGTGCCTTTCTGTCG-
GGATGT, V162 probe (TET labelled) – TTCACAAGT-
GCGTTTCTGTCGGGATGT.
G2528C Forward primer-TCCTTAAATATGGT-
GGAACACTTGAAG, Reverse primer-TCACAACCAC-
CAGTTTTGCAT, G2528 probe (FAM labelled) –
ATATCTAGTTTGGATTCAAAAGCTTCATTTCCCA, C2528
probe (TET labelled) – ATATCTAGTTTCGAT-
TCAAAAGCTTCATTTCCCA.
Statistics
For each clinical measure the mean was determined from
multiple measures obtained up to a maximum period of
three years (up to two years prior to enrolment, and up to
one year following enrolment). LDL cholesterol was esti-
mated through the use of the Freidwald equation. Linear
regression was used to determine the association of geno-
type with each measure corrected for age at genotyping.
For determining the association of genotype with age of
diagnosis, this was corrected for gender and presence of a
history of smoking by determining residuals and adding
these to the overall mean age of diagnosis. Cox's propor-
tional hazards was used to model time to first event. All
individuals were followed from the point of genotyping
until a non-fatal myocardial infarction occurred, or a
composite of non-fatal myocardial infarct or all cause
death. Censoring occurred either at the end of the study or
death from any cause. Both variants were included in the
model and it was found that a co-dominant model for
each variant produced the best fit. The following variables
were also included in the model; age at genotyping, gen-
der, history of smoking, treatment with insulin, a previous
history of a myocardial infarction, prevalent angina and
prevalent cerebrovascular disease. Haplotype frequency
estimates together with haplotype effects were determined
using the THESIAS Program [28,29]. In the case of survival
analysis by haplotype using THESIAS only age at genotyp-
ing, prevalent angina and a previous history of a myocar-
dial infarction were included in the model.
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